RareCyte Precision Biology Services
Full-Service Provider for Spatial Biology and Liquid Biopsy Solutions
RareCyte is a full-service provider of Precision Biology™ services utilizing best in class platforms for spatial biology and liquid biopsy. We deliver quality-focused, end-to-end services from custom assay development to clinical trial testing for researchers, translational scientists, and drug development and diagnostics organizations. Contact us to begin your program →
Spatial Biology Services
Liquid Biopsy Services
New assay services
- γH2AX CTC assay. Download the γH2AX specification sheet →
- PSMA CTC assay. Download the PSMA specification sheet →
- HER3 CTC assay. Download the HER3 specification sheet →
Why work with us?
A simple process to obtain the high-quality data you need. Utilizing our extensive expertise in assay development and clinical trials, our team delivers high quality data and is responsive and flexible to meet your program needs. Programs are constructed as milestone-based plans based on client requirements and structured to meet defined timelines and budgets.
RareCyte infrastructure comprises of a CLIA-accredited laboratory, ISO 13485:2016 certification and a rigorous Quality Management System to support all levels of assay development and deployment.
Program
Planning
Logistics
Management
Comprehensive
Assessment
Data Analysis
and Reporting
Qualified Service Providers for Clinical Trials Development
RareCyte Qualified Service Providers (QSPs) include a network of global contract research organizations (CROs) that enable retrospective and prospective clinical studies. QSPs provide sample processing, sample storage, circulating tumor cell analysis services, spatial biology services, and undergo continual training, testing, and certification to ensure data quality consistent with submission to regulatory bodies.
Spatial Biology Services
Spatial Biology services with the Orion™ Spatial Biology Platform enable comprehensive phenotypic immunoprofiling in whole slide specimens, characterization of tissue architecture, investigation of tumor heterogeneity, and quantitative assessment of biomarker expression. This fast, pathology-grade technology provides highly multiplexed biological tissue analysis. Our team works with you to determine program requirements, define custom panels and clinical sample testing, with options to select from our list of qualified biomarkers, add, or exchange your target biomarkers. With scientific rigor and under pathologist guidance, our team will rapidly deliver high quality results for your program.
Liquid Biopsy Services: Rare Cell Analysis for Clinical Trials and Drug Development
Full-service Liquid Biopsy programs support all aspects of rare cell analysis from the development of protein-based custom multi-biomarker assays to single cell and plasma molecular analysis, including drug targets and pharmacodynamic markers and sample testing for clinical studies in our CLIA-certified laboratory. Our end-to-end platform delivers exquisitely sensitive, specific, accurate, and reproducible data. Programs begin with pilot assay development, followed by disease-specific validation studies to support exploratory clinical trials. We then execute reagent- and sample- stability studies, and development of control materials to support RUO, CLIA and CDx deployment of the novel assay.
RareCyte is a registered scientist.com supplier.
